Partial Thromboplastin Time
"Partial Thromboplastin Time" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy.
| Descriptor ID |
D010314
|
| MeSH Number(s) |
E01.370.225.625.115.600 E05.200.625.115.600 G09.188.660
|
| Concept/Terms |
Kaolin-Cephalin Coagulation Time- Kaolin-Cephalin Coagulation Time
- Coagulation Time, Kaolin-Cephalin
- Kaolin Cephalin Coagulation Time
- Coagulation Time, Cephalin-Kaolin
- Coagulation Time, Cephalin Kaolin
- Cephalin-Kaolin Coagulation Time
- Cephalin Kaolin Coagulation Time
|
Below are MeSH descriptors whose meaning is more general than "Partial Thromboplastin Time".
Below are MeSH descriptors whose meaning is more specific than "Partial Thromboplastin Time".
This graph shows the total number of publications written about "Partial Thromboplastin Time" by people in this website by year, and whether "Partial Thromboplastin Time" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Partial Thromboplastin Time" by people in Profiles.
-
Varying Dosages of Subcutaneous Unfractionated Heparin and Activated Partial Thromboplastin Time in Hospitalized Antepartum Patients: A Retrospective Cohort Analysis. Anesth Analg. 2022 05 01; 134(5):1028-1034.
-
Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban. Arch Pathol Lab Med. 2022 01 02; 146(2):145-153.
-
Coagulation factor abnormalities related to discordance between anti-factor Xa and activated partial thromboplastin time in patients supported with continuous-flow left ventricular assist devices. J Heart Lung Transplant. 2016 11; 35(11):1311-1320.
-
Treatment of hemolysis with intravenous unfractionated heparin using an antifactor Xa-based monitoring protocol. J Thorac Cardiovasc Surg. 2015 May; 149(5):1465-6.
-
Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support. JACC Heart Fail. 2015 Apr; 3(4):314-22.
-
Intravenous thrombolysis in a stroke patient taking dabigatran. J Stroke Cerebrovasc Dis. 2012 Nov; 21(8):916.e11-2.
-
Heparin resistance in acute coronary syndromes. J Thromb Thrombolysis. 2007 Apr; 23(2):93-100.
-
Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus) III. Clinical laboratory values. Am J Trop Med Hyg. 2006 Jun; 74(6):1084-9.
-
Thoracic epidural anesthesia and cardiac surgery: balancing postoperative risks associated with hematoma formation and thromboembolic phenomenon. J Cardiothorac Vasc Anesth. 2005 Dec; 19(6):768-71.
-
Acquired factor VIII inhibitor presenting as a tongue hematoma. J Emerg Med. 2004 May; 26(4):411-4.